Gardasil vaccine

Gardasil is a major pharmaceutical product used globally for the prevention of certain strains of Human Papillomavirus (HPV). It was developed through a collaborative effort involving researchers from the University of Queensland in Australia, Georgetown University Medical Center, the University of Rochester, and the U.S. National Cancer Institute. The brand has become a cornerstone of preventive medicine in oncology and reproductive health.

The manufacturing process for Gardasil is sophisticated, involving recombinant DNA technology. Merck & Co. maintains primary manufacturing operations in the United States, particularly in Pennsylvania, while also utilizing significant international facilities in Ireland and Puerto Rico to meet global demand. This distributed supply chain ensures that the vaccine is available across various continents.

Ownership of Gardasil remains with Merck & Co., Inc. (known as MSD outside the U.S. and Canada). The company is one of the world's largest healthcare providers, focusing on prescription medicines, vaccines, and biologic therapies. As the brand moves into 2026 and beyond, the owner continues to focus on expanding the distribution of the 9-valent version (Gardasil 9) to further reduce the global burden of HPV-related cancers.